Quoted from the $EAPH website: "We believe that the products we are developing will be classified as cosmetics or Class I medical devices. Products classified as cosmetics may be marketed and sold in the US without FDA approval. Drugs are not cosmetics and those, as well as OTC drugs, must be marketed following FDA regulations and/or approvals in the United States. Before human testing can begin with respect to a new drug in the United States, preclinical studies are conducted in laboratory animals to evaluate the potential efficacy and the safety of a product. Human clinical studies generally involve a three-phase process. The initial clinical evaluation, Phase I, consists of administering the product and testing for safe and tolerable dosage levels. Phase II trials continue the evaluation of safety and determine the appropriate dosage for the product, identify possible side effects and risks in a larger group of subjects, and provide preliminary indications of efficacy. Phase III trials consist of testing for actual clinical efficacy within an expanded group of patients at geographically dispersed test sites."
Quoted from the $EAPH website: "We believe that the
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
GTT Voting Rights Disclosure: Key Insights and Data Unveiled
Understanding GTT's Share Capital and Voting Rights In the realm of corporate governance, transparency regarding voting rights and shares plays a crucial role in building trust among investors. This month, we delve into the comprehensive details regarding the total number of shares and voting rights for GTT. Key Disclosure Details This important monthly disclosure...
Continue Reading
Go North Hemp Anticipates Significant Revenue Surge in 2025
Anticipating Revenue Growth at Go North Hemp Go North Hemp, a prominent wholesale supplier of hemp-derived ingredients, has announced its ambitious projection for the year 2025: a remarkable 100% year-over-year revenue increase compared to 2024. This growth is attributed to the rising consumer demand for its innovative range of products, including EPN (Euphorinol), CBG,...
Continue Reading
Ezee Fiber Commences $400 Million Fiber Network Expansion
Ezee Fiber's Major Expansion into New Markets Ezee Fiber, renowned for delivering high-speed multi-gig internet services, has recently announced an investment of over $400 million aimed at expanding its fiber-to-the-premises network. This exciting development will see the company's services reaching more homes and businesses across the Greater Puget Sound region. The CEO...
Continue Reading
John Hancock Preferred Income II's Shares Surge to New Highs
John Hancock Preferred Income II Reaches New Milestone In an impressive display of resilience, John Hancock Preferred Income II (HPF) stock has reached a remarkable 52-week high, currently trading at $18.88 USD. This new peak is significant, reflecting a substantial 36.5% change in the stock's price over the year. The sharp increase in value indicates heightened investor...
Continue Reading
Fed Rate Cuts Spark Market Surge and New Investment Dynamics
Federal Reserve's Transformative Rate Decision Recent activity in the financial markets has captured the attention of both investors and analysts. Following the Federal Reserve's choice to cut interest rates by 0.5%, we're starting to see significant changes in market dynamics. This reduction initiates a much-anticipated rate-cutting cycle, which could influence the...
Continue Reading